SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in ...

(RTTNews) - Sanofi Winthrop Industrie announced that positive results from the HERCULES phase 3 study, published in The New England Journal of Medicine (NEJM), showed that tolebrutinib delayed ...

An experimental drug can delay disability progression in advanced multiple sclerosis patients Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple ...

Tolebrutinib is a BTK inhibitor that is being studied for the treatment of relapsing multiple sclerosis. New research findings comparing tolebrutinib with teriflunomide are summarized in a short ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...